ascopubs.org

Impact of variant allele frequency (VAF) of TP53 alterations and Signatera circulating tumor DNA (ctDNA) monitoring for patients (pts) with advanced urothelial carcinoma (aUC ...

Comprehensive investigation of CPSF3's role in the progression of bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a ...
Seeking Alpha

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory ...
ascopubs.org

Development of a Machine Learning Model for Aspyre Lung Blood: A New Assay for Rapid Detection of Actionable Variants From Plasma in Patients With Non–Small Cell Lung Cancer

Development and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study Data ...
MedPage Today

Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations

In this exclusive MedPage Today video, Virginia Kaklamani, MD, DSc, of UT Health Sciences Center in San Antonio and co-director of the San Antonio Breast Cancer Symposium (SABCS), discusses a subgroup ...
Cure Today

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

Promising Biomarker Reductions: Treatment with the MDM2 inhibitor navtemadlin led to significant reductions in key biomarkers of disease severity, including circulating CD34+ cells, a hallmark of ...